EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK

Sheng-Chia Chung iD, Alvina Lai iD, Gregory Y H Lip, Pier D Lambiase iD, Rui Providencia iD

EP Europace · 2023

DOI: 10.1093/europace/euac155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EP Europace, 2023. Verfasst von Sheng-Chia Chung und 4 weiteren Autor:innen. Beteiligte Einrichtung: UCL Institute of Health Informatics Research, University College London, 222 Euston Rd, London NW1 2DA, UK. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Failure, Catheter Ablation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Research Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Utilizing real-world UK data, we aimed to understand: (i) whether anti-arrhythmic drugs and catheter ablation are effective in improving the survival of atrial fibrillation (AF) patients and (ii) which rhythm control option produces better results for the whole AF population and for specific groups of patients, stratified by age, sex, and history of heart failure. Methods and results We identified 199 433 individuals (mean age at diagnosis 75.7 ± 12.7 years; 50.2% women) with new-onset AF diagnosis in nationwide electronic health records linking primary care consultation with hospital data and death registry data from 1998 to 2016. We investigated the survival and causes of death of new-onset AF patients receiving vs. not-receiving rhythm control therapies. During a median follow-up of 2.7 (0.7–6.0) years, we observed a significantly lower mortality in patients receiving rhythm control [multivariate-adjusted hazard ratio (HR) = 0.86, 95% confidence interval (CI) 0.84–0.88]. Pulmonary vein isolation was associated with a two-third significant mortality reduction compared with no rhythm control (HR = 0.36, 95% CI 0.28–0.48), flecainide with 50% reduction (HR = 0.52, 95% CI 0.48–0.57), and propafenone and sotalol with reduction by a third (HR = 0.63, 95% CI 0.50–0.81, 0.71, 95% CI 0.68–0.74, respectively). Amiodarone showed no survival benefit in individuals <70 years (HR = 0.99, 95% CI 0.97–1.02). Otherwise, the effect of rhythm control on survival did not differ by age, sex, nor history of heart failure.

Conclusion

Among individuals with new-onset AF, favourable survival was observed for patients receiving rhythm control treatment. Among different rhythm control strategies, pulmonary vein isolation showed the most pronounced survival benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHeart FailureCatheter AblationHumansFemaleMiddle AgedAgedAged, 80 and overMaleAnti-Arrhythmia AgentsUnited KingdomTreatment Outcome

Stichwörter der Autor:innen

Anti-arrhythmic agentsArrhythmiaMortalityPulmonary vein isolationRhythm control

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • UCL Institute of Health Informatics Research, University College London, 222 Euston Rd, London NW1 2DA, UK.
  • Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • UCL Institute of Cardiovascular Science University College London, London, UK.
  • St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London, UK.

ORCID-Profile: Sheng-Chia Chung, Alvina Lai, Pier D Lambiase, Rui Providencia

Förderung

  • British Heart Foundation
  • Research Development

Zitieren

APA

Chung, S. C., Lai, A., Lip, G. Y. H., Lambiase, P. D., & Providencia, R. (2023). Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK. EP Europace. https://doi.org/10.1093/europace/euac155

Vancouver

Chung SC, Lai A, Lip GYH, Lambiase PD, Providencia R. Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK. EP Europace. 2023. doi:10.1093/europace/euac155

BibTeX
@article{Chung2023,
  author = {Chung, Sheng-Chia and Lai, Alvina and Lip, Gregory Y H and Lambiase, Pier D and Providencia, Rui},
  title = {Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK},
  journal = {EP Europace},
  year = {2023},
  doi = {10.1093/europace/euac155}
}
Kostenlos starten →